Wolfgang Oster
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$3.8MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $3.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 6, 2018 | NIH | SBIR Phase II Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $714K | ONCOCEUTICS, INC. |
| Aug 30, 2018 | NIH | SBIR Phase II Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $4K | ONCOCEUTICS, INC. |
| Aug 28, 2018 | NIH | SBIR Phase II Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma | $1000K | ONCOCEUTICS, INC. |
| Aug 11, 2017 | NIH | SBIR Phase II Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $224K | ONCOCEUTICS, INC. |
| Dec 23, 2016 | NIH | SBIR Phase II Clinical efficacy of the antitumor agent ONC201 in GBM | $225K | ONCOCEUTICS, INC. |
| Aug 2, 2016 | NIH | SBIR Phase II Clinical efficacy of the antitumor agent ONC201 in GBM | $553K | ONCOCEUTICS, INC. |
| Aug 25, 2015 | NIH | SBIR Phase II Clinical efficacy of the antitumor agent ONC201 in GBM | $847K | ONCOCEUTICS, INC. |
| Mar 19, 2015 | NIH | SBIR Phase II Clinical efficacy of the antitumor agent ONC201 in GBM | $210K | ONCOCEUTICS, INC. |
Peer ranks
Federal funding#430
Awards as PI#190
Patents#273
Companies
- ONCOCEUTICS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.